Post-market surveillance evaluation of authorized generic drug products (U01)
Post Date
April 29th 2014
Application Due Date
June 21st 2014
Funding Opportunity Number
RFA-FD-14-013
CFDA Number(s)
93.103
Funding Instrument Type(s)
Cooperative Agreement
Funding Activity Categories
Health
Science and Technology and other Research and Development
Number of Awards
2
Eligibility Categories
State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other
Unrestricted
FOREIGN INSTITUTIONS ARE ELIGIBLE TO APPLY
Funding
-
Estimated Total Funding:
$400000
-
Award Range:
$350000 - $400000
Grant Description
The purpose of this study is to evaluate existing tools and to develop new methods to monitor the drug safety, efficacy, usage, and substitution patterns of model authorized generics in different therapeutic categories in comparison with those of brand name drugs and other generic drugs. The outcome of this study will help determine whether any potential bias against generic drugs is involved in generic drug complaints and affects generic substitution.
Contact Information
-
Agency
Department of Health and Human Services
-
Office:
Food and Drug Administration
-
Agency Contact:
Martin Bernard
Grants Management Specialist
Phone 240-402-7564 -
Agency Mailing Address:
FDA OFFICE
- Agency Email Address:
- More Information:
Get A Free Grant Assistance Kit
To start your application for a free grant package go to: